Syncona's Achilles' heel: struggling biopharma holding goes bust
Biopharma Achilles' liquidation provides another blow to struggling life sciences trust Syncona.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
Biopharma Achilles' liquidation provides another blow to struggling life sciences trust Syncona.
The real estate trust, which yields 6%, has enjoyed an uplift in both its value and rents as it slashes its exposure to offices.
Shareholders in European Smaller Companies have voted against activist investor Boaz Weinstein's bid to oust its board.
In what is now the sixth successive defeat for Saba Capital Management in its bid to take control of seven London listed investment companies, shareho...
Manager Neil Hermon takes advantage of market volatility caused by the Budget, adding seven stocks to the portfolio.
While aggressive buybacks have kept Nick Train’s Finsbury Growth & Income off Saba’s target list, next year’s continuation vote could prove pointless.
AVI Japan Opportunity Trust (AJOT) says that it has received a tender offer bid aimed at privatising one of its portfolio companies, Tecnos Japan Inco...
Syncona (SYNC) says that its portfolio company, Spur Therapeutics (Spur) has announced positive new data from its Phase I/II GALILEO-1 study of FLT201...
Syncona (SYNC) says that its portfolio company, Achilles Therapeutics Plc, has announced that its board has recommended a members’ solvent voluntary l...
Cordiant Digital Infrastructure (CORD) has announced that a subsidiary of its portfolio company, Speed Fibre DAC, has entered into a put and call agre...
JPMorgan Global Growth & Income’s ascent continues, with the £3.1bn trust only just behind Scottish Mortgage in popularity on platforms.
In QuotedData’s morning briefing 5 February 2025: Third Point Investors has published its investor letter for Q4 2024. Third Point’s flagship Offshore...
Developed by Moore-Wilson